36P6D5: secreted tumor antigen

US7507541B2 · kind B2 · utility

Assignee

• Latency, LLC · US

Inventors

• Arthur B. Raitano · Los Angeles, US
• Aya Jakobovits · Beverly Hills, US
• Mary Faris · Los Angeles, US
• Daniel Afar · Santa Monica, US
• Rene S. Hubert · Los Angeles, US
• Steve Chappell Mitchell · Santa Monica, US

Key dates

• Filing date: May 24, 2007
• Grant date: Mar 24, 2009
• Expiry date: May 24, 2027

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described is a gene and its encoded secreted tumor antigen, termed 36P6D5, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express 36P6D5, particularly including cancers of the bladder, kidney, prostate, breast, colon, ovary and pancreas.